A Preoperative Prognostic Model for Patients Treated with Nephrectomy for Renal Cell Carcinoma

European Urology

Volumn 55, Issue 2, 2009, Pages 287-295

  Karakiewicz, Pierre I ^a   Suardi, Nazareno ^a,b   Capitanio, Umberto ^a,b   Jeldres, Claudio ^a   Ficarra, Vincenzo ^c   Cindolo, Luca ^d   de la Taille, Alexandre ^e   Tostain, Jacques ^f   Mulders, Peter F A ^g   Bensalah, Karim ^h   Artibani, Walter ^c   Salomon, Laurent ^e   Zigeuner, Richard ⁱ   Valéri, Antoine ^j   Descotes, Jean Luc ^j   Rambeaud, Jean Jacques ^k   Méjean, Arnaud ^l   Montorsi, Francesco ^b   Bertini, Roberto ^b   Patard, Jean Jacques ^h  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d G RUMMO HOSPITAL   (Italy)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^g RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

^j FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^k UNIV GRENOBLE ALPES   (France)

^l Necker Medical School   (France)

more..

Author keywords

Decision making; Nomogram; Pre treatment; Renal cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ANALYSIS OF VARIANCE; CARCINOMA, RENAL CELL; CAUSE OF DEATH; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEPHRECTOMY; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; SURVIVORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 57649192405     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.07.037     Document Type: Article

References (30)

1. Yaycioglu O., Roberts W.W., Chan T., et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58 (2001) 141-145
2. Cindolo L., de la Taille A., Messina G., et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 92 (2003) 901-905
3. Patard J.J., Leray E., Cindolo L., et al. Multi-institutional validation of a symptom-based classification for renal cell carcinoma. J Urol 172 (2004) 858-862
4. Grambsch P.M., Therneau T.M., and Fleming T.R. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 51 (1995) 1469-1482
5. Fine J.P., and Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Statistical Assoc 94 (1999) 496-509
6. Harrell Jr. F.E., Califf R.M., Pryor D.B., Lee K.L., and Rosati R.A. Evaluating the yield of medical tests. JAMA 247 (1982) 2543-2546
7. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
8. Atkinson A.C. A note on the generalized information criterion for choice of a model. Biometrika 67 (1980) 413-418
9. Kirkali Z. The motion: open partial nephrectomy is the standard of care for small resectable solid renal masses. Eur Urol 51 (2007) 561-564 discussion 564
10. Lesage K., Joniau S., Fransis K., and Van Poppel H. Comparison between open partial and radical nephrectomy for renal tumours: perioperative outcome and health-related quality of life. Eur Urol 51 (2007) 614-620
11. Bhojani N., Jeldres C., Patard J.-J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53 (2008) 917-930
12. Hafron J., and Kaouk J.H. Ablative techniques for the management of kidney cancer. Nat Clin Pract Urol 4 (2007) 261-269
13. Abou Youssif T., Kassouf W., Steinberg J., et al. Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer 110 (2007) 1010-1014
14. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
15. Pantuck A.J., Belldegrun A.S., and Figlin R.A. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?. Clin Cancer Res 13 (2007) 693s-696s
16. Kader A.K., Tamboli P., Luongo T., et al. Cytoreductive nephrectomy in the elderly patient: the M.D. Anderson Cancer Center experience. J Urol 177 (2007) 855-860 discussion 860
17. Antonelli A., Cozzoli A., Nicolai M., et al. Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm. Eur Urol 53 (2008) 803-809
18. Karakiewicz P.I., Suardi N., Jeldres C., et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 53 (2008) 845-848
19. Sulser T. Is kidney surgery going to be minimally invasive in all cases?. Eur Urol 52 (2007) 1549-1553
20. Skolarikos A., Alivizatos G., Laguna P., and de la Rosette J. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol 51 (2007) 1490-1501 discussion 1501
21. Ficarra V. Open radical nephrectomy versus open partial nephrectomy: is it still an issue?. Eur Urol 51 (2007) 593-595
22. Walz J., Gallina A., Saad F., et al. A nomogram predicting 10-yr life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 25 (2007) 3576-3581
23. Karakiewicz P.I., Briganti A., Chun F.K., et al. Multi-institutional validation of a new RCC-specific survival nomogram. J Clin Oncol 25 (2007) 1316-1322
24. Capitanio U., Jeldres C., Shariat S.F., and Karakiewicz P. Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. Eur Urollume 54 (2008) 958-959
25. Cindolo L., Patard J.J., Chiodini P., et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104 (2005) 1362-1371
26. Terrone C., and Volpe A. The role of pathology for clinical decision-making in renal cell carcinoma is increasing. Eur Urol 51 (2007) 1166-1168 discussion 1168-70
27. Frank I., Blute M.L., Cheville J.C., et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 170 (2003) 2225-2232
28. Zisman A., Pantuck A.J., Wieder J., et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20 (2002) 4559-4566
29. Han K.R., Bleumer I., Pantuck A.J., et al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 170 (2003) 2221-2224
30. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477